Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $107.10 | Total: $535.50 |
| 1 | 10 | $90.72 | Total: $907.20 |
| 1 | 25 | $76.86 | Total: $1,921.50 |
| 1 | 50 | $65.52 | Total: $3,276.00 |
| 1 | 100 | $56.70 | Total: $5,670.00 |
Overview
JAK2-IN-7, a selective inhibitor targeting Janus Kinase 2 (JAK2), exhibits inhibitory concentrations (IC50) of 3 nM for JAK2, 11.7 nM for SET-2 cells, and 41 nM for BaF3 V617F cells, indicative of its potency and selectivity. This compound demonstrates more than 14-fold selectivity against JAK1, JAK3, and FLT3, underlining its specificity. JAK2-IN-7 effectively induces cell cycle arrest at the G0G1 phase and promotes apoptosis in tumor cells, manifesting significant antitumor activities [1].
Chemical Properties
| Molecular Formula | C26H33N7O |
| Molecular Weight | 459.59 |
| CAS Numbers | 2593402-36-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(C=CCN(C)C)(=O)N1CC=2C(=CC(NC=3N=C(C(C)=CN3)C4=CN(C(C)C)N=C4)=CC2)CC1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Yang T, et al. N-[Pyrimidin-2-yl]-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms [published online ahead of print, 2020 Nov 30]. J Med Chem. 2020;10.1021acs.jmedchem.0c01488.